Geode Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.94M | Buy |
5,299,457
+2,776,343
| +110% | +$3.84M | ﹤0.01% | 2736 |
|
|
2026
Q1 | $3.99M | Buy |
2,523,114
+61,921
| +3% | +$104K | ﹤0.01% | 2856 |
|
|
2025
Q4 | $4.11M | Buy |
2,461,193
+41,427
| +2% | +$71.7K | ﹤0.01% | 2877 |
|
|
2025
Q3 | $4.09M | Sell |
2,419,766
-11,853
| -0.5% | -$14K | ﹤0.01% | 2887 |
|
|
2025
Q2 | $2.21M | Sell |
2,431,619
-2,053,967
| -46% | -$1.22M | ﹤0.01% | 3110 |
|
|
2025
Q1 | $2.03M | Buy |
4,485,586
+795,100
| +22% | +$466K | ﹤0.01% | 3026 |
|
|
2024
Q4 | $1.85M | Buy |
3,690,486
+11,206
| +0.3% | +$8.23K | ﹤0.01% | 3158 |
|
|
2024
Q3 | $3.33M | Buy |
3,679,280
+83,274
| +2% | +$77.2K | ﹤0.01% | 2950 |
|
|
2024
Q2 | $3.59M | Buy |
3,596,006
+342,950
| +11% | +$379K | ﹤0.01% | 2902 |
|
|
2024
Q1 | $4.82M | Buy |
3,253,056
+317,245
| +11% | +$360K | ﹤0.01% | 2726 |
|
|
2023
Q4 | $3.2M | Buy |
2,935,811
+168,874
| +6% | +$185K | ﹤0.01% | 2917 |
|
|
2023
Q3 | $3.27M | Buy |
2,766,937
+346,129
| +14% | +$471K | ﹤0.01% | 2860 |
|
|
2023
Q2 | $3.41M | Buy |
2,420,808
+1,138,808
| +89% | +$1.57M | ﹤0.01% | 2899 |
|
|
2023
Q1 | $1.92M | Buy |
1,282,000
+17,591
| +1% | +$24.6K | ﹤0.01% | 3046 |
|
|
2022
Q4 | $1.48M | Buy |
1,264,409
+13,253
| +1% | +$16.7K | ﹤0.01% | 3183 |
|
|
2022
Q3 | $1.41M | Buy |
1,251,156
+1,784
| +0.1% | +$2.62K | ﹤0.01% | 3219 |
|
|
2022
Q2 | $1.97M | Sell |
1,249,372
-1,026,601
| -45% | -$1.35M | ﹤0.01% | 3114 |
|
|
2022
Q1 | $3.5M | Sell |
2,275,973
-54,178
| -2% | -$84.1K | ﹤0.01% | 2982 |
|
|
2021
Q4 | $5.71M | Sell |
2,330,151
-11,363
| -0.5% | -$26.6K | ﹤0.01% | 2827 |
|
|
2021
Q3 | $5.9M | Buy |
2,341,514
+2,930
| +0.1% | +$7.52K | ﹤0.01% | 2811 |
|
|
2021
Q2 | $6.66M | Buy |
2,338,584
+1,072,633
| +85% | +$2.78M | ﹤0.01% | 2738 |
|
|
2021
Q1 | $2.97M | Buy |
1,265,951
+200,662
| +19% | +$482K | ﹤0.01% | 3059 |
|
|
2020
Q4 | $1.87M | Buy |
1,065,289
+43,745
| +4% | +$61.2K | ﹤0.01% | 3121 |
|
|
2020
Q3 | $956K | Hold |
1,021,544
| – | – | ﹤0.01% | 3229 |
|
|
2020
Q2 | $888K | Sell |
1,021,544
-655,975
| -39% | -$577K | ﹤0.01% | 3178 |
|
|
2020
Q1 | $1.39M | Buy |
1,677,519
+108,792
| +7% | +$108K | ﹤0.01% | 2869 |
|
|
2019
Q4 | $1.4M | Buy |
1,568,727
+27,939
| +2% | +$23.3K | ﹤0.01% | 3151 |
|
|
2019
Q3 | $1.51M | Sell |
1,540,788
-4,381
| -0.3% | -$4.54K | ﹤0.01% | 3074 |
|
|
2019
Q2 | $1.7M | Buy |
1,545,169
+92,863
| +6% | +$107K | ﹤0.01% | 3045 |
|
|
2019
Q1 | $1.9M | Buy |
1,452,306
+224,766
| +18% | +$280K | ﹤0.01% | 2884 |
|
|
2018
Q4 | $1.12M | Sell |
1,227,540
-132,928
| -10% | -$204K | ﹤0.01% | 3066 |
|
|
2018
Q3 | $2.8M | Buy |
1,360,468
+32,962
| +2% | +$69.2K | ﹤0.01% | 2702 |
|
|
2018
Q2 | $2.39M | Buy |
1,327,506
+61,477
| +5% | +$124K | ﹤0.01% | 2753 |
|
|
2018
Q1 | $2.98M | Buy |
1,266,029
+6,613
| +0.5% | +$15.5K | ﹤0.01% | 2540 |
|
|
2017
Q4 | $2.37M | Buy |
1,259,416
+39,047
| +3% | +$85.3K | ﹤0.01% | 2652 |
|
|
2017
Q3 | $3.03M | Buy |
1,220,369
+12,378
| +1% | +$30.7K | ﹤0.01% | 2499 |
|
|
2017
Q2 | $3.33M | Buy |
1,207,991
+15,410
| +1% | +$43.1K | ﹤0.01% | 2428 |
|
|
2017
Q1 | $3.6M | Buy |
1,192,581
+733,072
| +160% | +$2.08M | ﹤0.01% | 2307 |
|
|
2016
Q4 | $1.45M | Buy |
459,509
+19,013
| +4% | +$58.4K | ﹤0.01% | 2810 |
|
|
2016
Q3 | $1.5M | Buy |
440,496
+17,299
| +4% | +$47.8K | ﹤0.01% | 2720 |
|
|
2016
Q2 | $966K | Buy |
423,197
+14,093
| +3% | +$34.6K | ﹤0.01% | 2917 |
|
|
2016
Q1 | $1.03K | Sell |
409,104
-30,522
| -7% | -$68.1K | ﹤0.01% | 2867 |
|
|
2015
Q4 | $1.45M | Buy |
439,626
+30,058
| +7% | +$89.8K | ﹤0.01% | 2678 |
|
|
2015
Q3 | $991K | Buy |
409,568
+51,704
| +14% | +$134K | ﹤0.01% | 2874 |
|
|
2015
Q2 | $1.05M | Buy |
357,864
+2,404
| +0.7% | +$9.32K | ﹤0.01% | 2870 |
|
|
2015
Q1 | $1.43M | Buy |
355,460
+18,742
| +6% | +$64.8K | ﹤0.01% | 2660 |
|
|
2014
Q4 | $1.01M | Buy |
336,718
+5,748
| +2% | +$15.5K | ﹤0.01% | 2838 |
|
|
2014
Q3 | $838K | Buy |
330,970
+83,524
| +34% | +$201K | ﹤0.01% | 2884 |
|
|
2014
Q2 | $609K | Buy |
247,446
+18,122
| +8% | +$40.9K | ﹤0.01% | 3065 |
|
|
2014
Q1 | $608K | Buy |
229,324
+62,197
| +37% | +$183K | ﹤0.01% | 3060 |
|
|
2013
Q4 | $485K | Hold |
167,127
| – | – | ﹤0.01% | 3109 |
|
|
2013
Q3 | $513K | Buy |
167,127
+6,153
| +4% | +$19.5K | ﹤0.01% | 2935 |
|
|
2013
Q2 | $514K | Buy |
+160,974
| New | +$516K | ﹤0.01% | 2857 |
|
Other funds holding LCTX
BC
DC
Geode Capital Management's LCTX Position: Q2 2026 in Review
Geode Capital Management increased its Lineage Cell Therapeutics (LCTX) stake by 110% in Q2 2026, buying an estimated $3.84M and bringing the position to 5,299,457 shares worth $6.94M. The position accounts for ﹤0.01% of the portfolio, ranked #2736.
Geode Capital Management first reported a position in LCTX in Q2 2013 and has held it in 53 quarters since. 126 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.
- Geode Capital Management held 5,299,457 shares of Lineage Cell Therapeutics worth $6.94M as of Q2 2026.
- Geode Capital Management bought 2,776,343 Lineage Cell Therapeutics shares in Q2 2026, an estimated $3.84M.
- Lineage Cell Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #2736 holding.
- Geode Capital Management first reported a position in Lineage Cell Therapeutics in Q2 2013 and has held it in 53 quarters since.
- 126 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.